Allos Therapeutics to Report 2008 First Quarter Financial Results on May 7, 2008
April 24 2008 - 3:00PM
Business Wire
Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that it
will report 2008 first quarter financial results on Wednesday, May
7, 2008, before the U.S. financial markets open. Paul L. Berns,
President and Chief Executive Officer, and other members of Allos'
senior management will provide a company update and discuss results
via webcast and conference call on Wednesday, May 7, 2008 at 8:30
AM ET. The webcast of this call will be available from the homepage
and the investors/media section of the Company's website,
www.allos.com, and will be archived for 30 days. Alternatively,
callers may participate in the conference call by dialing
800-762-8779 (domestic) or 480-248-5081 (international). Webcast
and telephone replays of the conference call will be available
approximately two hours after the completion of the call through
Friday, May 16, 2008. Callers can access the replay by dialing
800-406-7325 (domestic) or 303-590-3030 (international). The
passcode is 3865346. About Allos Therapeutics Allos Therapeutics is
a biopharmaceutical company focused on developing and
commercializing small molecule therapeutics for the treatment of
cancer.�The Company's lead product candidate, PDX (pralatrexate),
is a novel antifolate currently under evaluation in a pivotal Phase
2 (PROPEL) trial in patients with relapsed or refractory peripheral
T-cell lymphoma. The PROPEL trial is being conducted under an
agreement reached with the U.S. Food and Drug Administration under
its special protocol assessment, or SPA, process. The Company is
also investigating PDX in patients with non-small cell lung cancer
and a range of lymphoma sub-types. The Company's other product
candidate�is RH1, a targeted chemotherapeutic agent currently being
evaluated in a Phase 1 trial in patients with advanced solid tumors
or non-Hodgkin�s Lymphoma (NHL). For additional information, please
visit the Company�s website at www.allos.com. Safe Harbor Statement
The 2008 first quarter results press release and conference call
will contain forward-looking statements that involve significant
risks and uncertainties. Additional information concerning these
forward-looking statements and other factors that may cause actual
results to differ materially from those anticipated in the
forward-looking statements is contained in the "Risk Factors"
section of the Company's Annual Report on Form 10-K for the year
ended December 31, 2007 and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in the press release or the
conference call. All forward-looking statements are based on
information currently available to the Company on the date thereof,
and the Company undertakes no obligation to revise or update these
forward-looking statements to reflect events or circumstances after
the date of this presentation, except as required by law.
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Allos Therapeutics, Inc. (MM) (NASDAQ): 0 recent articles
More Allos Therapeutics, Inc. News Articles